COMPARATIVE CHARACTERISTICS OF SOME LIPID METABOLISM AND ENDOTHELIAL FUNCTION INDICES IN THE PATIENTS WITH COMPENSATED CHRONIC COR PULMONALE OF BRONCHO-PULMONARY GENESIS AND IN CONDITIONS OF ITS COMORBIDITY WITH HYPERTENSIVE DISEASE

Petrov Ye. Ye., Burmak Yu. G., Treumova S. I., Ivanytska T. A.

CLINICAL AND EXPERIMENTAL MEDICINE

Scentific article

The indices of lipid metabolism and endothelial function in 64 patients with chronic obstructive pulmonary disease (COPD) and compensated chronic cor pulmonale (CCP) (female – 22, male – 42, mean age – 54,8± 2,5) have been studied and analyzed. The patients were subdivided into two groups: the comparative group which comprised 32 patients and the main group consisted of 32 patients with сomorbid hypertensive disease (HD) of the II stage, of the 2 degree of arterial hypertension. The patients of the both groups were of the same sex, age and duration of disease’s course. The treatment of the both CCP of broncho-pulmonary genesis and HD was given in accordance with the requirements of the protocol. The obtained research results in the patients of the main and comparative groups were compared in groups and also with the indices of practically healthy individuals (n = 15) of the same sex and age. It has been established that the patients with compensated CCP of broncho-pulmonary genesis had the increase of triglycerides, total cholesterol, low-density lipoprotein (LDL) cholesterol, the decrease of high-density lipoprotein (HDL) cholesterol, LDL/HDL cholesterol ratio in comparison with the practically healthy individuals, but these changes weren’t significant and showed only a tendency. At the same time, the changes of lipid metabolism indices in the patients with compensated CCP and comorbid HD were more significant – the cholesterol content was 5,8±0,6 mmol/l, LDL cholesterol – 4,8±0,5 mmol/l. They exceeded the indices among healthy individuals in 1,4 times (р˃0,05) and 1,5 times (р<0,05), accordingly; and in comparison with the comparative group they were increased in 1,2 times (р˃0,05) and 1,3 times (р<0,05), accordingly. Moreover, the patients of the main group had a significant decrease of the HDL cholesterol content (1,4±0,02 mmol/l) – in 1,3 times in comparison with healthy individuals and downward tendency in comparison with the comparative group (1,6±0,04 mmol/l). Unlike patients with compensated CCP of broncho-pulmonary genesis, whose atherogenic index (2,2±0,2) tended to be higher in comparison with practically healthy individuals (1,7±0,3), LDL/HDL cholesterol ratio among the patients of the main group (3,4±0,1) was 2 times as high as among practically healthy individuals and 1,5 times as high as among the patients of the comparative group (р<0,001). It reflects the proatherogenic direction of lipid metabolism’s changes quantitatively and qualitatively. A significant decrease of NOx both in the patients of the comparative group (26,5±1,2 mmol/l) and the patients with comorbidity (16,2±1,3 mmol/l) (р<0,001) in comparison with practically healthy individuals (36,3±0,8 mmol/l) has been established in the further research of the total content of the stable metabolites of nitrogen oxide (NOx) in blood serum. Besides, the content of NOx among the patients of the main group was 1,6 times as low as among the patients of the comparative group (р<0,001). The direction of endothelin-1 (ET-1) changes was opposite. Its maximal point was observed in the patients with the compensated CCP of broncho-pulmonary genesis with comorbid HD (5,2±0,1 pmol/l). It was 1,3 times (р<0,001) as high as the same index among the patients of the comparative group(4,0±0,4 pmol/l) and 1,6 times as high as (р<0,001) one among the practically healthy individuals (3,2±0,5 pmol/l). The established changes of endothelial function indices (the decrease of NOx content and the increase ЕТ-1) in the patients with compensated CCP of broncho-pulmonary genesis reflect a disorder of regulatory endothelial function and testify about their maximal significance in the patients with comorbid course of CCP and HD. Conclusions. 1. The origin of lipid metabolism changes in the patients with compensated CCP of broncho-pulmonary genesis reflects generally their proatherogenic tendency, and maximal significance of these changes is typical of the patients with comorbid HD. 2. The diagnosed changes of lipid metabolism in the patients with compensated CCP of broncho-pulmonary genesis are combined with significant disorders of regulatory endothelial function, besides maximal significance of endothelial dysfunction manifestations is observed in the patients with comorbid HD. 3. The origin and direction of the changes of lipid metabolism and endothelial function in the patients with compensated CCP of broncho-pulmonary genesis should be considered as markers of unfavorable development of the vascular sclerosis and the increased risk of the vascular complications.

chronic cor pulmonale, hypertensive disease, comorbidity, lipid metabolism, endothelial function

1. Mostovoy YuM. Khronichne obstruktyvne zakhvoryuvannya lehen. Klyuchovi pytannya. Ukr. med. chasopys. 2016 Serp 25;4(114):63-5. [in Ukrainian].
2. Konoplʹova LF, Rudenko YuV. Khronichne leheneve sertse. U kn.: Amosova KM, redaktor. Vnutrishnya medytsyna. Kyyiv: Medytsyna; 2009;2:158-78. [in Ukrainian].
3. Pavlov P, Ivanov Y, Glogovska P, Popova T, Borisova E, Nozharov V. Cardiovascular comorbidity in patients with chronic obstructive pulmonary disease. Eur Respir J. 2012 Sep 1;40(56):986.
4. Berezin AYe. Khronicheskaya obstruktivnaya bolezn legkikh i kardiovaskulyarnyy risk. Ukr. med. chasopys. 2009;2(70):62-9. [in Russian].
5. Caughey GE, Ramsay EN, Vitry AI, Gilbert AL, Luszcz MA, Ryan P, et al. Comorbid chronic diseases, discordant impact on mortality in older people: a 14-year longitudinal population study. J Epidemiol Community Health. 2010 Dec;64(12):1036-42.
6. Chandy D, Aronow WS, Banach M. Current perspectives on treatment of hypertensive patients with chronic obstructive pulmonary disease. Itepr. Blood Press. Control. 2013;6:101-9.
7. Titov VN, Kukharchuk VV, Rozhkova TA, Susekov AV, Solov’yоva YеYu. Effektivnost’ i perenosimost’ statinov u bol’nykh s pervichnymi giperlipidemiyami v ambulatornoy klinicheskoy praktike. Kardiologiya. 2005;9:32-4. [in Russian].
8. Mancia G, de Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. Guidelines 2007. Guidelines for the Management of Arterial Hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007;6(25):1101-87.
9. Treumova SI, Petrov YeYe, Boryak VP. Kliniko-laboratorni osoblyvosti perebihu khronichnoho obstruktyvnoho zakhvoryuvannya lehenʹ u poyednanni z ishemichnoyu khvoroboyu sertsya na tli metabolichnoho syndromu. Visnyk problem biolohiyi і medytsyny. 2015;1(3):218-22. [in Ukrainian].
10. Poulain M, Doucet M, Drapeau V, Fournier G, Tremblay A, Poirier P, et al. Metabolic and inflammatory profile in obese patients with chronic obstructive pulmonary disease. Chron Respir Dis. 2008;5(1):35-41.
11. Patel AR, Hurst JR. Extrapulmonary comorbidities in chronic obstructive pulmonary disease: state of the art. Expert Review of Respiratory Medicine. 2011;5(5):647-62.
12. Khronichne obstruktyvne zakhvoryuvannya leheni. Adaptovana klinichna nastanova, zasnovana na dokazakh: Nakaz MOZ Ukrayiny vid 27 chervnya 2013 № 555 [Internet]. Dostupno: http://mtd.dec.gov.ua/images/dodatki/2013_555_HOZL/2013_555_hozl_kn.pdf [in Ukrainian].
13. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report. COLD Executive Summary. Am J Respir Crit Care Med. 2017 Mar 1;195(5):557-82.
14. Gavrisyuk VK. Khronicheskoye legochnoye serdtse: mekhanizmy patogeneza i printsipy terapii. Ukrainskiy pulmonologicheskiy zhurnal. 2007;1:9-10. [in Russian].
15. Nastanova ta klinichnyy protokol nadannya medychnoyi dopomohy «Arterialna hipertenziya». K.; 2012. 107 s. [in Ukrainian].
16. Mancia G, Fagard R, Narkiewicy K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. Eur. Heart J. 2013 Jul 21;34(28):2159-219.
17. Malaya LT, Korzh AN, Balkovaya LB. Endotelial’naya disfunktsiya pri patologii serdechno-sosudistoy sistemy. Khar’kov: Torsing; 2000. 432 s. [in Russian].
18. Martynov AI, Avetyan NG, Akatova YeV. Disfunktsiya endoteliya u bol’nykh gipertonicheskoy bolezn’yu. Kardiologiya. 2005;10(45):101-4. [in Russian].
19. Kazakov YuM, Treumova SI, Petrov YeYe. Rolʹ endotelialʹnoyi dysfunktsiyi v rozvytku khronichnoho lehenevoho sertsya. Poltava: TOV «Firma«Tekhservis»; 2016. 146 s. [in Ukrainian].
20. Kolomiyets VV, Vankhanen NV, Bobrova YеV, Bekker PF, Sulayeva TA. Vliyaniye atorvastatina na funktsiyu endoteliya u bol’nykh s ishemicheskoy bolezn’yu serdtsa i arterial’noy gipertenziyey. Ukr. kardiol. zhurn. 2006;3:83-7. [in Russian].
21. Lemko OI, Vantyukh NV. Endotelialʹna dysfunktsiya ta yiyi mistse v patohenezi khronichnoho obstruktyvnoho zakhvoryuvannya lehenʹ (Chastyna I). Ukr. terapevt. zhurn. 2017;2:91-7. [in Ukrainian].
22. Polverino F, Celli BR, Owen CA. COPD as an endothelial disorder: endothelial injury linking lesions in the lungs and other organs? (2017 Grover Conference Series). Pulm Circ. 2018 Jan-Mar;8(1):2045894018758528.

«Bulletin of problems biology and medicine» Issue 1 (155), 2020 year, 179-182 pages, index UDK 616.12-008.331.1-009.72:612.397

10.29254/2077-4214-2020-1-155-179-182